UNSPSC 51263131: Pafenolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AEP5YJ9MZ. European Medicines Agency schedules Pafenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09585MIG. Pafenolol generally arises in the molecular formula C18H31N3O3. The term PAFENOLOL is an International Non-Proprietary Name or INN. PAFENOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule pafenolol under HS 29242190 and SITC 51473. As of Q4 2014, PAFENOLOL remains the US FDA Preferred Term for this commodity. Pafenolol bears US NLM identifiers UMLS ID C0069942 and NCI Concept Code C66291. SMILES: O(CC(O)CNC(C)C)C1CCC(CCNC(=O)NC(C)C)CC1.

UNSPSC 51263131 Pafenolol, a Commodity code, does not align with the recent state and local procurement activity posted under it. The single identified opportunity — Seminole County, Florida's IFB for naloxone and drug deactivation systems — involves emergency medical supplies and harm-reduction equipment unrelated to pafenolol, a beta-blocking pharmaceutical used in cardiovascular treatment. The mismatch suggests either a data-classification error in the source or inconsistent UNSPSC tagging by the issuing body.

The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford, Florida, with a two-year initial term and one-year renewal option. The code shows little relevant recent activity under its nominal pharmaceutical scope, making it difficult to characterize current state and local buying patterns, issuing-body mix, or geographic concentration for pafenolol itself.